Condition: COVID-19 Infection · Sponsor: Pfizer
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study intervention administration but do not require supplemental oxygen for COVID-19.
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| Hope Clinical Research, Inc. | Canoga Park, California, United States | Recruiting |
| Amicis Research Center - Granada Hills | Granada Hills, California, United States | Recruiting |
| Jacobs Medical Center at UC San Diego Health | La Jolla, California, United States | Recruiting |
| UC Davis CTSC Clinical Research Center | Sacramento, California, United States | Recruiting |
| University of California Davis Health | Sacramento, California, United States | Recruiting |
| UC San Diego Medical Center - Hillcrest | San Diego, California, United States | Recruiting |
| University of California San Diego Health | San Diego, California, United States | Recruiting |
| UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| University of Colorado Clinical and Translational Research Center | Aurora, Colorado, United States | Recruiting |
| University of Colorado Hospital | Aurora, Colorado, United States | Recruiting |
| Georgetown University Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
+ 136 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07013474